Literature DB >> 16896822

Addition of a macrolide to a ss-lactam in bacteremic pneumococcal pneumonia.

R Dwyer1, A Ortqvist, E Aufwerber, B Henriques Normark, T J Marrie, M A Mufson, A Torres, M A Woodhead, M Alenius, M Kalin.   

Abstract

In the study presented here, data collected prospectively from 340 adult patients hospitalised in five countries with bacteremic pneumococcal CAP and treated with a ss-lactam +/- a macrolide were analysed retrospectively to evaluate the efficacy of this antimicrobial combination. Univariate and multivariate analyses revealed no significant effect on case fatality rate when a macrolide/ss-lactam regimen was used as initial therapy. Results were not affected by severity of illness, or by excluding patients who died within 2 days of admission. Identified predictors of death in a multivariate regression model were age >65 years (OR=2.6), two or more lung lobes affected (OR=2.2), and severity of disease as estimated using the acute physiology score (APS)>8.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16896822     DOI: 10.1007/s10096-006-0183-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

1.  Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

Authors:  H K Johansen; T G Jensen; R B Dessau; B Lundgren; N Frimodt-Moller
Journal:  J Antimicrob Chemother       Date:  2000-12       Impact factor: 5.790

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia?

Authors:  Thomas M File; Lionel A Mandell
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

4.  Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.

Authors:  José A Martínez; Juan P Horcajada; Manuel Almela; Francesc Marco; Alex Soriano; Elisa García; Maria Angeles Marco; Antoni Torres; Josep Mensa
Journal:  Clin Infect Dis       Date:  2003-01-31       Impact factor: 9.079

5.  Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997.

Authors:  M A Mufson; R J Stanek
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

6.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.

Authors:  P P Gleason; T P Meehan; J M Fine; D H Galusha; M J Fine
Journal:  Arch Intern Med       Date:  1999-11-22

7.  Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia.

Authors:  G W Waterer; G W Somes; R G Wunderink
Journal:  Arch Intern Med       Date:  2001 Aug 13-27

8.  Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro.

Authors:  Eugene Lin; Ronald J Stanek; Maurice A Mufson
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

9.  Legionnaires disease with bacteremic coinfection.

Authors:  Michael J Tan; James S Tan; Thomas M File
Journal:  Clin Infect Dis       Date:  2002-07-31       Impact factor: 9.079

10.  Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.

Authors:  Richard B Brown; Paul Iannini; Peter Gross; Mark Kunkel
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

View more
  13 in total

Review 1.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  What Is New in Antibiotic Therapy in Community-Acquired Pneumonia? An Evidence-Based Approach Focusing on Combined Therapy.

Authors:  Simone Gattarello
Journal:  Curr Infect Dis Rep       Date:  2015-10       Impact factor: 3.725

3.  Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.

Authors:  Thomas P Lodise; Andrea Kwa; Leon Cosler; Reetu Gupta; Raymond P Smith
Journal:  Antimicrob Agents Chemother       Date:  2007-08-20       Impact factor: 5.191

4.  Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.

Authors:  Elena Laserna; Oriol Sibila; Juan Felipe Fernandez; Diego Jose Maselli; Eric M Mortensen; Antonio Anzueto; Grant Waterer; Marcos I Restrepo
Journal:  Chest       Date:  2014-05       Impact factor: 9.410

Review 5.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

6.  Using cluster analysis of cytokines to identify patterns of inflammation in hospitalized patients with community-acquired pneumonia: a pilot study.

Authors:  Timothy L Wiemken; Robert R Kelley; Rafael Fernandez-Botran; William A Mattingly; Forest W Arnold; Stephen P Furmanek; Marcos I Restrepo; James D Chalmers; Paula Peyrani; Rodrigo Cavallazzi; Jose Bordon; Stefano Aliberti; Julio A Ramirez
Journal:  Univ Louisville J Respir Infect       Date:  2017-01-30

7.  Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study.

Authors:  Nicolas Mongardon; Adeline Max; Adrien Bouglé; Frédéric Pène; Virginie Lemiale; Julien Charpentier; Alain Cariou; Jean-Daniel Chiche; Jean-Pierre Bedos; Jean-Paul Mira
Journal:  Crit Care       Date:  2012-08-15       Impact factor: 9.097

8.  Combination antibiotic therapy for community-acquired pneumonia.

Authors:  Jesus Caballero; Jordi Rello
Journal:  Ann Intensive Care       Date:  2011-11-23       Impact factor: 6.925

9.  Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.

Authors:  Christophe Adrie; Carole Schwebel; Maïté Garrouste-Orgeas; Lucile Vignoud; Benjamin Planquette; Elie Azoulay; Hatem Kallel; Michael Darmon; Bertrand Souweine; Anh-Tuan Dinh-Xuan; Samir Jamali; Jean-Ralph Zahar; Jean-François Timsit
Journal:  Crit Care       Date:  2013-11-07       Impact factor: 9.097

10.  Lung inflammatory pattern and antibiotic treatment in pneumonia.

Authors:  María-José Lorenzo; Inés Moret; Benjamín Sarria; Enrique Cases; Julio Cortijo; Raúl Méndez; Jose Molina; Alejandra Gimeno; Rosario Menéndez
Journal:  Respir Res       Date:  2015-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.